Table 1.
Comparison of glycemic control, lipid profile, hepatorenal functions and oxidative stress among diabetic patients on mono and combined anti-diabetic therapy.
| Diabetic patients on combined therapy N = 40Median (Q1–Q3) |
Diabetic patients on Metformin monotherapy N = 40Median (Q1–Q3) |
P | |
|---|---|---|---|
| Glycemic control | |||
| FBG (mmol/L) | 9.00 (7.30–10.68) | 7.61 (6.70–8.89) | .022* |
| HBA1c (%) | 8.20 (7.20–9.75) | 7.00 (6.40–7.65) | <.001* |
| Oxidative stress | |||
| LPD (nmol/dl) | 22.00 (20.00–23.00) | 21.00 (20.00–24.00) | .888 |
| TAC (nmol/ml) | 70.94 (67.00–73.02) | 70.64 (67.37–74.41) | .751 |
| Lipid profile | |||
| Triglycerides (mmol/L) | 1.70 (1.13–2.58) | 1.50 (1.30–2.16) | .582 |
| Cholesterol (mmol/L) | 5.00 (4.50–5.60) | 5.00 (4.20–5.68) | .599 |
| HDL (mmol/L) | 2.65 (2.01–3.60) | 2.65 (2.00–3.40) | .630 |
| LDL (mmol/L) | 1.05 (0.94–1.38) | 1.20 (0.94–1.50) | .498 |
| Hepatorenal functions | |||
| ALT (IU) | 22.50 (17.70–34) | 24.00 (15.00–34.00) | .841 |
| AST (IU) | 18.00 (14.93–21.75) | 16.00 (14.00–23.50) | .898 |
| Creatinine (mmol/L) | 58.50 (47.25–75.00) | 58.00 (43.00–71.00) | .563 |
FBG: fasting blood glucose; HBA1c: haemoglobin A1c; LPD: lipid peroxidase; TAC: total antioxidant capacity; HDL: high density lipoproteins; LDL: low density lipoproteins; ALT: alanine transaminase; AST: aspartate transaminase.
*
Statistically significant.